A Novel Antibody Drug Conjugate for Metastatic Renal Cancer Treatment

Project Summary The incidence of renal cell cancer has been rising steadily and for those that have tumor recurrence after surgery, the prognosis is generally poor. In 2013 an estimated 65,150 new cases and 13,680 deaths will be attributed to renal cancerin the United States. Renal cancer is the most common malignancy of the adult kidney and accounts for 2-3% of all adult malignancies. Of these, 33% of patients have metastatic disease at presentation, and 40% of the individuals undergoing a surgical resection eventually develop metastases. Of those who develop metastatic renal cancer, treatment options are limited, with typical median-survival rates between 7-9 months. In recent years, significant improvements in metastatic renal cancer treatment have beenreported with the use of immunotherapy and targeted therapies; however, for those who do not respond to these treatments or are not eligible for them, the prognosis is dismal. Recent alternatives in cancer treatment include antibody-drug conjugates (ADC's